PKM and non-small cell lung carcinoma: Wang et al. [22] demonstrated that hypoxia exacerbated cisplatin resistance in NSCLC cells and hypoxia-induced EVs PKM2 transmitted cisplatin resistance to sensitive NSCLC cells in vitro and in vivo; thus, EVs PKM2 may be a promising therapeutic target for cisplatin resistance in NSCLC.